CN110279757A - Weight reducing compound and preparation method thereof - Google Patents
Weight reducing compound and preparation method thereof Download PDFInfo
- Publication number
- CN110279757A CN110279757A CN201910444697.4A CN201910444697A CN110279757A CN 110279757 A CN110279757 A CN 110279757A CN 201910444697 A CN201910444697 A CN 201910444697A CN 110279757 A CN110279757 A CN 110279757A
- Authority
- CN
- China
- Prior art keywords
- extract
- root bark
- reducing compound
- weight reducing
- bark extract
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/11—Aldehydes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/65—Paeoniaceae (Peony family), e.g. Chinese peony
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/71—Ranunculaceae (Buttercup family), e.g. larkspur, hepatica, hydrastis, columbine or goldenseal
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Botany (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Biotechnology (AREA)
- Alternative & Traditional Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Child & Adolescent Psychology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
The present invention provides a kind of Weight reducing compound and preparation method thereof, belong to health care technology field, Weight reducing compound includes the moutan root bark extract containing paeonol derivative, preparation method include: will in cortex moutan powder be added comprising acid anhydrides, pyridine, ethyl alcohol, water extracting solution in, then microwave treatment after mixing is extracted and obtains extracting solution, is concentrated into medicinal extract, drying is to get moutan root bark extract；Hot water will be added in tea leaf powder, Microwave Extraction obtains extracting solution, is concentrated into medicinal extract, dry to get extract；Moutan root bark extract and tea extract are uniformly mixed to get Weight reducing compound.The lipid that Weight reducing compound moutan root bark extract of the present invention can reduce fat cell is formed, reduce the number and volume of mature fat cell, significantly inhibit fatty acid synthesis, accelerate intake and oxidation of the mitochondria to free fatty acid, gain effect is played with tea extract, to have unexpected significant antiobesity action.
Description
Technical field
The invention belongs to health care technology fields, and in particular to Weight reducing compound and preparation method thereof.
Background technique
Obesity also known as obesity, English name are " obesity ", it is inherent cause and environmental factor collective effect institute
Caused Nutrition and Metabolism obstacle disease mainly shows the energy balance state that human body energy intake is greater than consumption, to lead
A kind of disease symptoms caused by cause body fat accumulation excessively.It is current fat that oneself is become global public health and is asked
Topic, International Obesity ad hoc working group (TOTF) point out, fat to become new century threat human health and life satisfaction degree most
Big killer.Obesity harm is mainly manifested in two aspects, is that visceral adipose tissue Fat Accumulation itself is excessive first, leads to fat
The decline of cell storage ability cannot store more extra lipids, carbohydrate etc., the rouge content raising of blood lipid and other organs, danger
Evil health.Mesentery and the fat mass of internal organ attachment increase, and also will affect the function of internal organs.Secondly as adipose tissue is made
A large amount of inhibition rouge can be secreted once Fat Accumulation itself is excessive for a kind of presence of secretory, especially visceral adipose tissue
The cell factor of fat and musculature function, these cell factors mainly include free fatty acid, inflammatory factor, phylaxin and
Active oxygen etc..Cell factor can directly act on fat cell in the form of autocrine and paracrine, it is made to generate insulin
Resistance, disorder glycolipid metabolism；Can also pass into blood act on muscle cell generate insulin resistance, reduce its energy storage and
The ability of consumption, or the organs such as pancreas are acted on, damage its function.Therefore, inhibit the proliferation of fat cell and differentiation is to inhibit
A fat very important approach, and find the common aspiration that efficient fat-reducing medicament has become medical field.Existing market
On have fat-reducing dietic medicinal various in style, and constantly there is new drug to come out, but be mostly chemicals, some drugs can be bright
Some toxic side effects are brought aobviously, such as can generate different degrees of hepatic injury, and some synthesis class drug side effects are small, but effect
It is bad.Fat hyperlipidemia person needs lifelong medication treatment, therefore sight is invested natural fat-reducing dietic medicinal by more and more people
Development and utilization.
Summary of the invention
The purpose of the present invention is to provide a kind of lipids that moutan root bark extract used can reduce fat cell to be formed,
The number and volume for reducing mature fat cell significantly inhibit the expression of fatty acid synthesis related gene, inhibit fatty acid synthesis,
The expression of fatty acid oxidation gene is raised, accelerates intake and oxidation of the mitochondria to free fatty acid, is played with tea extract
Gain effect, thus the Weight reducing compound with unexpected significant antiobesity action.
The technical solution that the present invention is taken to achieve the above object are as follows:
Weight reducing compound, including, moutan root bark extract；Contain Paeonol shown in formula (i) in moutan root bark extract
Derivative；
In formula, R is that methyl or R are selected from carbon atom number as 1 and the group containing halogen.Paeonol has many potential doctors
Purposes, but its lipophilicity, water-soluble low physicochemical characteristics are treated, its pharmacological activity and application are greatly limited, in drug system
The solubility of the height and drug of content directly affects curative effect quality again in agent, and contains Paeonol in present invention extract
Derivative can improve the solubility and bioavilability of Paeonol in water.Paeonol derivative include Paeonol glucose and
Four glycosidation derivants of galactolipin.Obesity shows as the change of adipocyte count increased with cell volume on microcosmic
Greatly, the amount of the number for determining fat cell of the differentiation of PECTORAL LIMB SKELETON, the triglycerides in fat cell determines
The volume of fat cell.The lipid that the above-mentioned extract containing paeonol derivative can reduce fat cell is formed, and is inhibited
3T3-L1 PECTORAL LIMB SKELETON proliferation and the differentiation to fat cell, induce the apoptosis of 3T3-L1 PECTORAL LIMB SKELETON, inhibit fat thin
The fat of born of the same parents generates, and reduces the physiological activity that lipid accumulates in liver and serum, has potential antiobesity action；Also can simultaneously
The enough steatolysis promoted into the ripe fat cell of 3T3-L1, reduces the number and volume of mature fat cell, to reduce intracellular sweet
Oily three ester contents, play the role of lower blood-fat and reduce weight.In addition, the above-mentioned extract containing paeonol derivative can significantly inhibit fat
The expression of sour synthesis related gene inhibits fatty acid synthesis；The expression of fatty acid oxidation gene can also be raised, mitochondria pair is accelerated
The intake and oxidation of free fatty acid；In short, to play antiobesity action by above-mentioned effect.
Preferably, also containing Paeonol in moutan root bark extract.Type-2 diabetes mellitus is fat common complication, red
Skin phenol can promote PPAR γ expression in pancreatic tissue to dramatically increase, and then inhibit JNK1 apoptotic signal access, and it is thin to reduce pancreas islet B
The further damage of born of the same parents；Paeonol can also enhance the expression of GLP-1 in pancreatic tissue, then enhance islet B cell by GLP-1
The expression of vital factor PDX-1 in Proliferation, Differentiation path promotes islet B cell Proliferation, Differentiation, participates in due to diabetes
The reconstruction and reparation of impaired islet tissue, to treat diabetes during obesity.
Preferably, Weight reducing compound further includes tea extract.Tea extract mainly passes through its main active
(such as catechin, caffeine) influences stomodaeal nervous system activity, increases human body energy dissipation and play antiobesity action.In addition, tea
Leaf extract can also absorb food nourishment composition by changing body lipid metabolism, appetite-suppressing, reducing body, and practice midwifery
Raw antiobesity action.
More preferably, tea extract includes aqueous extract below: green tea, black tea, dark green tea, Pu'er tea or oolong
Tea, or combinations thereof.
Still more preferably, composition contains the ingredient of following parts by weight: 5-50 parts of moutan root bark extract, tealeaves extract
0-20 parts of object.The effect of Weight reducing compound combination moutan root bark extract and tea extract, with unexpected significant
Antiobesity action, can be widely applied to preparation weight-reducing food, drug and/or health care product.
It is another object of the present invention to provide Paeonol and its derivatives in moutan root bark extract obtained by a kind of raising
The yield of object makes the yield of paeonol derivative in moutan root bark extract obtained not less than 0.5%, and the yield of Paeonol is not
The preparation method of Weight reducing compound lower than 1.3%.
The technical solution that the present invention is taken to achieve the above object are as follows:
The preparation method of Weight reducing compound, comprising:
S1: including in the extracting solution of acid anhydrides, pyridine, ethyl alcohol, water, after mixing at microwave by being added in cortex moutan powder
Then reason is extracted and obtains extracting solution, medicinal extract is concentrated into, dry to get moutan root bark extract；
S2: will be added hot water in tea leaf powder, Microwave Extraction obtains extracting solution after mixing, be concentrated into medicinal extract, dry, i.e.,
Obtain extract；
S3: the moutan root bark extract and tea extract are uniformly mixed to get Weight reducing compound.
Microwave auxiliary extraction can obviously accelerate the dissolution rate of Cortex moutan, greatly shorten steam distillation
Time；S1 step extracting solution cooperation microwave treatment of the present invention makes the cell wall rapid disruption of cortex moutan, accelerates intracellular organic matter
To medium release, diffusion and dissolution, while the presence of acid anhydrides, pyridine can reduce the polarity of extracting solution in extracting solution, so that red
Solubility of the skin phenol in extracting solution increases, the final yield for improving Paeonol in gained moutan root bark extract；On the other hand
Can paeonol derivative shown in production (i) during the extraction process, can be sent out with the other components in moutan root bark extract
Gain effect is waved, the activity of moutan root bark extract is improved, gained extract is enable to significantly inhibit 3T3-L1 Preadipocyte In Vitro
Proliferation and differentiation, promote at the ripe fat cell of 3T3-L1 steatolysis, to play antiobesity action.
Preferably, S1 extracting solution is the ethyl alcohol of the 80-90% containing 0.1-0.4mM acid anhydrides and 7.0-30.0mM pyridine
Solution.Make the yield of paeonol derivative in moutan root bark extract obtained not less than 0.5% under this condition, Paeonol
Rate is not less than 1.3%.So that various effects of Weight reducing compound reach best.
Preferably, acid anhydrides is selected from least one of the compound with chemical structural formula shown in formula ii:
In formula, R is that methyl or R are selected from carbon atom number as 1 and the group containing halogen.More preferably, acid anhydrides is selected from acetic acid
At least one of acid anhydride, Trichloroacetic anhydride, trifluoroacetic anhydride, tribromoacetic acid acid anhydride, triiodoacetic acid acid anhydride.
Preferably, the solid-liquid ratio of cortex moutan powder and extracting solution is 1:12-18 (g/mL) in S1.
Preferably, microwave treatment power is 200-800w, time 3-5min in S1.
Compared with prior art, the invention has the benefit that preparation method of the present invention can reduce the polarity of extracting solution,
So that solubility of the Paeonol in extracting solution increases, it is final to improve Paeonol and its derivative in gained moutan root bark extract
Yield, make the yield of paeonol derivative in moutan root bark extract obtained not less than 0.5%, the yield of Paeonol is not low
In 1.3%, various effects of Weight reducing compound obtained is made to reach best；Weight reducing compound moutan root bark extract of the present invention
The lipid that fat cell can be reduced is formed, and the number and volume of mature fat cell are reduced, and significantly inhibits fatty acid synthesis phase
The expression of correlation gene inhibits fatty acid synthesis, raises the expression of fatty acid oxidation gene, accelerates mitochondria to free fatty acid
Intake and oxidation, to play antiobesity action；Weight reducing compound combination moutan root bark extract and tea extract of the present invention
Effect has unexpected significant antiobesity action, can be widely applied to food, drug and/or the health care of preparation weight-reducing
Product.
Present invention employs above-mentioned technical proposals to provide Weight reducing compound and preparation method thereof, compensates for the prior art not
Foot, reasonable design, easy operation.
Detailed description of the invention
Fig. 1 is the effect that moutan root bark extract is proliferated PECTORAL LIMB SKELETON and breaks up in test example 1 of the present invention；
Fig. 2 is influence of the moutan root bark extract to content of triglyceride in fat cell in test example 1 of the present invention；
Fig. 3 is influence of the moutan root bark extract to lipolysis in test example 1 of the present invention；
Fig. 4 is influence of the moutan root bark extract to the mouse of diet inducing obesity in test example 2 of the present invention.
Specific embodiment
Described below is to enable to have in field usually intellectual and understand and use of the invention and of the invention
Preferred embodiment.However, because general scope principle has been proposed in the present invention, so any scope that do not depart from
Obvious modification should all belong to the range of the present invention.
The present invention relates to a kind of Weight reducing compounds, including, moutan root bark extract；Contain formula in moutan root bark extract
(i) paeonol derivative shown in；
In formula, R is that be selected from carbon atom number be 1 and the group containing halogen by methyl or R, for example, formula (iii)-formula (vii),
Paeonol has many potential medical applications, but its lipophilicity, water-soluble low physicochemical characteristics, greatly
Its pharmacological activity and application are limited, the height of content and the solubility of drug directly affect good effect again in pharmaceutical preparation
It is bad, and Paeonol solubility in water and biological utilisation can be improved containing paeonol derivative in present invention extract
Degree.Paeonol derivative includes four glycosidation derivants of Paeonol glucose and galactolipin.Obesity is shown as on microcosmic
Increasing for adipocyte count and becoming larger for cell volume, the number for determining fat cell of the differentiation of PECTORAL LIMB SKELETON
The amount of mesh, the triglycerides in fat cell determines the volume of fat cell.The above-mentioned extract containing paeonol derivative
The lipid that fat cell can be reduced is formed, and 3T3-L1 PECTORAL LIMB SKELETON proliferation and the differentiation to fat cell, induction are inhibited
The apoptosis of 3T3-L1 PECTORAL LIMB SKELETON inhibits the fat of fat cell to generate, and reduces the life that lipid accumulates in liver and serum
Reason activity, has potential antiobesity action；The steatolysis of the ripe fat cell of 3T3-L1 can also be promoted into simultaneously, reduce mature fat
The number and volume of cell play the role of lower blood-fat and reduce weight to reduce intracellular triglyceride content.In addition, it is above-mentioned containing
The extract of paeonol derivative can significantly inhibit the expression of fatty acid synthesis related gene, inhibit fatty acid synthesis；Can also on
The expression of fatty acid oxidation gene is adjusted, intake and oxidation of the mitochondria to free fatty acid are accelerated；In short, to pass through above-mentioned work
With performance antiobesity action.
In the embodiment of the present invention, also contain Paeonol in moutan root bark extract, structural formula such as formula (viii),
Type-2 diabetes mellitus is fat common complication, and Paeonol can promote PPAR γ expression in pancreatic tissue to dramatically increase,
And then inhibit JNK1 apoptotic signal access, reduce the further damage of islet B cell；Paeonol can also enhance in pancreatic tissue
The expression of GLP-1, then by GLP-1 enhance islet B cell Proliferation, Differentiation path in vital factor PDX-1 expression,
Promote islet B cell Proliferation, Differentiation, participate in the reconstruction and reparation of the islet tissue impaired because of diabetes, thus in fat mistake
Diabetes are treated in journey.
In the embodiment of the present invention, Weight reducing compound further includes tea extract.
It is living that tea extract mainly passes through its main active (such as catechin, caffeine) influence stomodaeal nervous system
Property, increase human body energy dissipate and rise antiobesity action.In addition, tea extract can also be by changing body lipid metabolism, inhibiting
Appetite reduces body to food nourishment composition absorption, and generates antiobesity action indirectly.
In the embodiment of the present invention, tea extract includes aqueous extract below: green tea, black tea, dark green tea, Pu'er
Tea or oolong tea, or combinations thereof.
In the embodiment of the present invention, composition contains the ingredient of following parts by weight: 5-50 parts of moutan root bark extract (such as
6 parts, 10.5 parts, 15 parts, 20 parts, 25.4 parts, 30 parts, 33 parts, 36 parts, 39 parts, 42 parts etc.), 0-20 parts of tea extract (such as
0.2 part, 5 parts, 7 parts, 9 parts, 10.3 parts, 13 parts, 16 parts, 18 parts, 19 parts, 19.2 parts etc.).The Weight reducing compound combination tree peony root
The effect of bark extract and tea extract, has unexpected significant antiobesity action, can be widely applied to preparation and subtracts
Food, drug and/or the health care product of fertilizer.
In the embodiment of the present invention, the preparation method of Weight reducing compound, comprising:
S1: by solid-liquid ratio be 1:12-18 (g/mL) (such as 1:12.8,1:13,1:14,1:15.2,1:15.7,1:16,1:
17,1:17.5 etc.) it will addition include in the extracting solution of acid anhydrides, pyridine, ethyl alcohol, water, after mixing in 200- in cortex moutan powder
Microwave treatment 3-5min under 800w (such as 220w, 250w, 300w, 400w, 450w, 600w, 700w, 750w etc.), then in 40-
5-8h is extracted under 60 DEG C (such as 42 DEG C, 45 DEG C, 48 DEG C, 51 DEG C, 52 DEG C, 53 DEG C, 55 DEG C, 57 DEG C etc.) obtains extracting solution, concentration
It is dry to get moutan root bark extract to medicinal extract；Microwave auxiliary extraction can obviously accelerate the dissolution speed of Cortex moutan
Rate greatly shortens the time of steam distillation；
S2: by solid-liquid ratio 1:18-25 (g/mL) (such as 1:18.2,1:19,1:20,1:21.2,1:21.7,1:22,1:
23,1:24.5 etc.) hot water will be added in tea leaf powder, after mixing 200-800w (such as 220w, 250w, 300w, 400w,
450w, 600w, 700w, 750w etc.), 70-90 DEG C (such as 72 DEG C, 75 DEG C, 78 DEG C, 81 DEG C, 82 DEG C, 83 DEG C, 85 DEG C, 87 DEG C etc.)
Lower Microwave Extraction 6-15min obtains extracting solution, is concentrated into medicinal extract, dry to get extract；
S3: moutan root bark extract and tea extract are uniformly mixed to get Weight reducing compound.
S1 step extracting solution cooperation microwave treatment of the present invention makes the cell wall rapid disruption of cortex moutan, adds intracellular organic matter
Speed is discharged to medium, spreads and is dissolved, while the presence of acid anhydrides, pyridine can reduce the polarity of extracting solution in extracting solution, so that
Solubility of the Paeonol in extracting solution increases, the final yield for improving Paeonol in gained moutan root bark extract；Another party
Face can paeonol derivative shown in production (i) during the extraction process, can be with the other components in moutan root bark extract
Gain effect is played, the activity of moutan root bark extract is improved, so that gained extract is significantly inhibited 3T3-L1 precursor fatty thin
The proliferation and differentiation of born of the same parents promotes the steatolysis at the ripe fat cell of 3T3-L1, to play antiobesity action.
In the embodiment of the present invention, S1 extracting solution be containing 0.1-0.4mM (such as 0.12mM, 0.15mM, 0.23mM,
0.28mM, 0.3mM, 0.35mM etc.) acid anhydrides and 7.0-30.0mM (such as 7.5mM, 8.0mM, 8.4mM, 9.0mM, 10.0mM,
15.0mM, 20.0mM, 22.0mM, 25.0mM etc.) pyridine 80-90% (such as 81%, 82%, 83%, 85.8%, 86%,
88% etc.) ethanol solution.Under this condition it is not less than the yield of paeonol derivative in moutan root bark extract obtained
0.5%, the yield of Paeonol is not less than 1.3%.So that various effects of Weight reducing compound reach best.
In the embodiment of the present invention, acid anhydrides is selected from least one of the compound with chemical structural formula shown in formula ii:
In formula, R is that methyl or R are selected from carbon atom number as 1 and the group containing halogen.Above-mentioned acid anhydrides is selected from acetic anhydride, three
At least one of chloroacetic anhydride, trifluoroacetic anhydride, tribromoacetic acid acid anhydride, triiodoacetic acid acid anhydride.
In the following, being described further in conjunction with specific embodiments to embodiment of the present invention.
Embodiment 1:
The preparation method of Weight reducing compound, comprising:
S1: being that the extraction comprising acetic anhydride, pyridine, ethyl alcohol, water will be added in 1:12 (g/mL) in cortex moutan powder by solid-liquid ratio
In liquid, extracting solution is 80% ethanol solution containing 0.1mM acetic anhydride and 7.0mM pyridine, micro- at 200w after mixing
Wave handles 3min, then extracts 5h at 40 DEG C and obtains extracting solution, is concentrated into medicinal extract, dry to get moutan root bark extract；
S2: hot water will be added in green tea powder by solid-liquid ratio 1:18 (g/mL), microwave mentions at 200w, 70 DEG C after mixing
It takes 6min to obtain extracting solution, is concentrated into medicinal extract, it is dry to get extract；
S3: part moutan root bark extract of 5 parts by weight and the green-tea extract of 0 parts by weight are uniformly mixed to get weight-reducing
Composition.
Embodiment 2:
The preparation method of Weight reducing compound, comprising:
S1: being that the extraction comprising acetic anhydride, pyridine, ethyl alcohol, water will be added in 1:18 (g/mL) in cortex moutan powder by solid-liquid ratio
In liquid, extracting solution is 90% ethanol solution containing 0.4mM acetic anhydride and 30.0mM pyridine, micro- at 800w after mixing
Wave handles 5min, then extracts 8h at 60 DEG C and obtains extracting solution, is concentrated into medicinal extract, dry to get moutan root bark extract；
S2: hot water will be added in black tea powder by solid-liquid ratio 1:25 (g/mL), microwave mentions at 800w, 90 DEG C after mixing
It takes 15min to obtain extracting solution, is concentrated into medicinal extract, it is dry to get extract；
S3: part moutan root bark extract of 50 parts by weight and the black tea extract of 20 parts by weight are uniformly mixed to get subtracting
Fertilizer composition.
Embodiment 3:
The preparation method of Weight reducing compound, comprising:
S1: being that the extraction comprising acetic anhydride, pyridine, ethyl alcohol, water will be added in 1:15 (g/mL) in cortex moutan powder by solid-liquid ratio
In liquid, extracting solution is 85% ethanol solution containing 0.2mM acetic anhydride and 14.2mM pyridine, micro- at 500w after mixing
Wave handles 4min, then extracts 6h at 50 DEG C and obtains extracting solution, is concentrated into medicinal extract, dries to get moutan root bark extract,
In, the yield of formula viii substance is 1.42% and the yield of formula iii substance is 0.59%；
S2: hot water will be added in dark green tea powder by solid-liquid ratio 1:21 (g/mL), microwave mentions at 500w, 80 DEG C after mixing
It takes 10min to obtain extracting solution, is concentrated into medicinal extract, it is dry to get extract；
S3: part moutan root bark extract of 35 parts by weight and the black tea extract of 10 parts by weight are uniformly mixed to get subtracting
Fertilizer composition.
Above-mentioned moutan root bark extract is repeatedly extracted, is purified, formula viii substance and formula iii substance, structure are obtained
It is characterized as below:
Formula viii substance,1H-NMR(CDCl3) δ (ppm): 12.75 (1H, s, Ph-OH), 7.56 (1H, d, Ph-6H), 6.44
(1H,d,Ph-5H),6.40(1H,d,Ph-3H),3.87(3H,s,-OMe),2.24(3H,s,-COMe).ESI-MS m/z166
([M+1]+, 100%) and .Anal.Calcd for C9H10O3；
Formula iii substance,1H-NMR(CDCl3)δ(ppm):2.28(3H,s,-COMe),7.61(1H,d,Ph-6H),6.43
(1H,d,Ph-5H),6.41(1H,d,Ph-3H),3.83(3H,s,-OMe),2.54(3H,s,-COMe).ESI-MS m/z 208
([M+1]+, 100%) and .Anal.Calcd for C11H12O4.
Embodiment 4:
With embodiment 3 the difference is that: step 1) is Trichloroacetic anhydride with acid anhydrides, moutan root bark extract obtained
The formula iv substance that the formula viii substance and yield that middle yield is 1.44% are 0.56%.Formula iv substance,1H-NMR(CDCl3)δ
(ppm):7.61(1H,d,Ph-6H),6.43(1H,d,Ph-5H),6.41(1H,d,Ph-3H),3.83(3H,s,-OMe),2.54
(3H,s,-COMe).ESI-MS m/z 312([M+1]+, 100%) and .Anal.Calcd for C11H9O4Cl3.
Embodiment 5:
With embodiment 3 the difference is that: step 1) is trifluoroacetic anhydride with acid anhydrides, moutan root bark extract obtained
The yield of Chinese style viii substance is 1.46% and the yield of formula v substance is 0.55%.Formula v substance,1H-NMR(CDCl3)δ(ppm):
7.61(1H,d,Ph-6H),6.43(1H,d,Ph-5H),6.41(1H,d,Ph-3H),3.83(3H,s,-OMe),2.54(3H,
s,-COMe).ESI-MS m/z 262([M+1]+, 100%) and .Anal.Calcd for C11H9O4F3.
Embodiment 6:
With embodiment 3 the difference is that: step 1) is tribromoacetic acid acid anhydride, moutan root bark extract obtained with acid anhydrides
The yield of Chinese style viii substance is 1.45% and formula vi substance yield is 0.55%.Formula vi substance,1H-NMR(CDCl3)δ
(ppm):7.61(1H,d,Ph-6H),6.43(1H,d,Ph-5H),6.41(1H,d,Ph-3H),3.83(3H,s,-OMe),2.54
(3H,s,-COMe).ESI-MS m/z 445([M+1]+, 100%) and .Anal.Calcd for C11H9O4Br3.
Embodiment 7:
With embodiment 3 the difference is that: step 1) is triiodoacetic acid acid anhydride, moutan root bark extract obtained with acid anhydrides
Yield containing formula viii substance is 1.45% and the yield of formula vii substance is 0.54%.Formula vii substance,1H-NMR(CDCl3)δ
(ppm):7.61(1H,d,Ph-6H),6.43(1H,d,Ph-5H),6.41(1H,d,Ph-3H),3.83(3H,s,-OMe),2.54
(3H,s,-COMe).ESI-MS m/z 586([M+1]+, 100%) and .Anal.Calcd for C11H9O4I3.
Comparative example 1:
Compared with Example 3, the difference of this comparative example are as follows: step 1) is to contain 0.2mM acetic anhydride with extracting solution
85% ethanol solution, the yield of moutan root bark extract Chinese style viii substance obtained are 1.86%.
Comparative example 2:
Compared with Example 3, the difference of this comparative example are as follows: step 1) is to contain 14.2mM pyridine with extracting solution
85% ethanol solution, the yield of moutan root bark extract Chinese style viii substance obtained are 1.84%.
Comparative example 3:
Compared with Example 3, the difference of this comparative example are as follows: the ethanol solution that step 1) is 85% with extracting solution, system
The yield of the moutan root bark extract Chinese style viii substance obtained is 1.63%.
Comparative example 3 and comparative example 1-3 improve gained tree peony root it is found that the present invention is able to cooperate microwave treatment with extracting solution
The yield of Paeonol in bark extract, while paeonol derivative is generated during the extraction process.
Comparative example 4:
The preparation method of Weight reducing compound, comprising:
By solid-liquid ratio be 1:15 (g/mL) by cortex moutan powder be added comprising acetic anhydride, pyridine, ethyl alcohol, water extracting solution
In, extracting solution is 85% ethanol solution containing 0.2mM acetic anhydride and 14.2mM pyridine, after mixing the microwave at 500w
4min is handled, then 6h is extracted at 50 DEG C and obtains extracting solution, is concentrated into medicinal extract, it is dry to get moutan root bark extract, as
Weight reducing compound.
Test example 1:
Influence of the moutan root bark extract to fat cell
The effect that 1.MTT method measurement moutan root bark extract is proliferated PECTORAL LIMB SKELETON
After the digestion of 3T3-L1 PECTORAL LIMB SKELETON, with 1 × 104/ mL is inoculated in 96 well culture plates, for 24 hours after, it is real with 100 μ g/mL
It applies moutan root bark extract made from a 3-7 and comparative example 1-3 and handles 3T3-L1 PECTORAL LIMB SKELETON respectively for 24 hours.Then, it uses
Mtt assay examines cell viability.
MTT colorimetric method: inhaling the culture solution abandoned in culture hole, washed 2 times with PBS, and the culture of the solution containing MTT is added in every hole
Liquid, 37 DEG C, 5%CO2It is debated in incubator after educating 4 hours, occurs bluish violet crystal in culture hole, be centrifuged 10min under 2000rpm,
Supernatant is removed, solution is blotted, 100 μ L DMSO are added in every hole, and shaking table vibrates 10min, so that intracellular bluish violet crystal is completely molten
Solution, microplate reader 570nm survey absorbance.As a result (3 test group of 1- embodiment, 4 test group of 2- embodiment, 3- are real in figure as shown in Figure 1
Apply 5 test group of example, 6 test group of 4- embodiment, 7 test group of 5- embodiment, 1 control group of 6- comparative example, 2 control group of 7- comparative example,
3 control group of 8- comparative example), from figure 1 it appears that moutan root bark extract made from embodiment 3-7 is to fatty before 3T3-L1
The proliferation of cell has certain inhibiting effect, and moutan root bark extract made from comparative example 1-3 is thin to fat before 3T3-L1
The no inhibiting effect of the proliferation of born of the same parents, before this illustrates paeonol derivative that moutan root bark extract of the invention contains to 3T3-L1
The proliferation of fat cell is inhibited.
2. the effect that moutan root bark extract breaks up PECTORAL LIMB SKELETON
1) cell is taped against on 24 orifice plates, density is about 70-80%；
2) change 1 basal medium every other day (containing 10%FBS, 1% dual anti-DMEM high glucose medium)；
3) when cell is covered with to 100%, continue culture two days.
4) it the 0th day, changes induction culture medium into and (contains 10%FBS, 1% dual anti-, 10 μ g/ in DMEM high glucose medium
mL Insulin,1μM Dexamethasone,0.5mM BIMX)；
5) it the 2nd day, changes secondary differential medium into and (contains 10%FBS, 1% dual anti-, 10 μ g/ in DMEM high glucose medium
mL Insulin)；
6) 1 basal medium is changed respectively within the 4th, 6,8 day；
7) the embodiment 3-7 and comparative example 1-3 of 100 μ g/mL is added for the 0th day to the 3rd day in cell differentiation in the medium
Moutan root bark extract solution obtained observes cell fat drips accumulation using oil red O staining method on 8th day.Specific method is such as
Under: culture medium is sucked out, every hole is washed 3 times with 1mL PBS；1mL4% formaldehyde is added to fix 15min with every hole, ultrapure water cleans 3 times；Often
Hole adds 300 μ L oil red O stain liquid, sets room temperature on shaking table and dyes 30min, is washed 3 times with 1mL pure water, under the microscope, film recording；
Every hole adds 500 μ L isopropanols, sets room temperature on shaking table and extracts 15 minutes；200 hole μ L/ of extract is placed in 96 orifice plates, 510 measurements are inhaled
Light value calculates cell differentiation inhibiting rate, and calculation formula is as follows:
As a result (3 test group of 1- embodiment, 4 test group of 2- embodiment, 5 test group of 3- embodiment, 4- in figure as shown in Figure 1
6 test group of embodiment, 7 test group of 5- embodiment, 1 control group of 6- comparative example, 2 control group of 7- comparative example, 8- comparative example 3 compare
Group), from figure 1 it appears that moutan root bark extract made from embodiment 3-7 has the differentiation of 3T3-L1 PECTORAL LIMB SKELETON
Certain inhibiting effect, and moutan root bark extract made from comparative example 1-3 does not press down the differentiation of 3T3-L1 PECTORAL LIMB SKELETON
Production is used, this illustrates the differentiation of paeonol derivative that moutan root bark extract of the invention contains to 3T3-L1 PECTORAL LIMB SKELETON
It is inhibited.
3. influence of the moutan root bark extract to content of triglyceride in fat cell
Obesity shows as increasing for adipocyte count and becoming larger for fat cell volume on microcosmic, and in fat cell
The cruel amount of glycerol three determine the volume of fat cell.First by it is above-mentioned (2. moutan root bark extracts to PECTORAL LIMB SKELETON break up
Effect) step carries out induction differentiation to cell.The reality of 100 μ g/mL was added on the 2nd day in cell differentiation in the medium by the 3rd day
It applies moutan root bark extract solution made from a 3-7 and comparative example 1-3, at the 8th day, inhales and abandon culture medium, every hole 1mL PBS
It washes 3 times, adds 200 μ L cell pyrolysis liquids, measure triglycerides by kit method and protein content, calculation formula are as follows:
As a result (3 test group of 1- embodiment, 4 test group of 2- embodiment, 5 test group of 3- embodiment, 4- in figure as shown in Figure 2
6 test group of embodiment, 7 test group of 5- embodiment, 1 control group of 6- comparative example, 2 control group of 7- comparative example, 8- comparative example 3 compare
Group), from figure 2 it can be seen that utilizing moutan root bark extract pair made from embodiment 3-7 within first 4 days in cell induction differentiation
After PECTORAL LIMB SKELETON is handled, the content of intracellular triglycerides can reduce, moutan root bark made from comparative example 1-3 mentions
Object is taken to have little effect the content of intracellular triglycerides, this result and oil red coloration result are almost the same, further
Confirm that moutan root bark extract made from embodiment 3-7 is able to suppress PECTORAL LIMB SKELETON differentiation.
4. influence of the moutan root bark extract to lipolysis
After cell induction differentiation, at the 10th day, it is biggish fat drop in cell, can be used for measuring lipolysis.It inhales
Culture medium is abandoned, is washed 3 times with hank ' s buffer.It is incubated for inhale after 3h with the hank ' s containing 0.1%BSA and abandons culture medium.By 100 μ
Moutan root bark extract solution made from the embodiment 3-7 and comparative example 1-3 of g/mL is added to the hank ' s containing 2%BSA
In, cultivate 20h.Culture medium, 70 DEG C of heating water baths is sucked out, inactivating endogenous lipase is then centrifuged for.Take supernatant by kit mark
Quasi- method measures glycerol content.After cell cracking in 24 orifice plates, protein content is measured by kit method.Glycerol in culture medium
Content, calculation formula are as follows:
As a result (3 test group of 1- embodiment, 4 test group of 2- embodiment, 5 test group of 3- embodiment, 4- in figure as shown in Figure 3
6 test group of embodiment, 7 test group of 5- embodiment, 1 control group of 6- comparative example, 2 control group of 7- comparative example, 8- comparative example 3 compare
Group), it is secreted into culture medium from figure 3, it can be seen that moutan root bark extract made from embodiment 3-7 can increase fat cell
Glycerol amount, can preferably promote the lipolysis in fat cell, and moutan root bark extract made from comparative example 1-3
The effect for promoting its lipolysis is had no to mature fat cell.This illustrates the root bark of tree peony that moutan root bark extract of the invention contains
Amphyl has facilitation to lipolysis.
Test example 2:
Influence of the moutan root bark extract to the mouse to diet inducing obesity
100 four week old male mices are put into nursing generic word material 7d in animal house, adapt it to experimental situation.Then
10 low fat control group mices are selected to feed low fat word material low fat control group (the low fat feed of raising 10%) at random, more than 90 is only small
Mouse feeds word material high in fat (word supports 45% word material high in fat), records weight weekly, after 8 weeks, claims mouse weight.High lipid food will be fed
Mouse is randomly divided into group: control group high in fat；Embodiment 3-7 test group；Comparative example 1-3 control group.4 every cages of mouse, environment 22
± 2 DEG C, humidity 30-70%, mouse ad lib and drinking-water；Experiment lasts 8 weeks, and record weight is primary within every 7 days, records within every 3 days
Mouse ingests and water intake.After 8 weeks, mouse fasting is weighed afterwards for 24 hours, is taken blood, cervical dislocation to put to death with posterior orbit, is taken ventral groove subcutaneous
And epididymis peripheral adipose, it quickly takes liver organization and is placed in -80 DEG C of refrigerators and save backup.
1. Mouse Liver sample is placed on progress homogeneous operation in phosphate buffer, according to the operating procedure of detection kit
Mouse liver SOD, GPx content are detected respectively.
2.TRlzol method extracts sample total serum IgE, is designed RNA reverse transcription according to gene order at cDNA with random primer
Specific primer (such as table 1), using SYBR GREEN dye method, is with β-action by the method for real-time fluorescence quantitative PCR
Reference gene does the expression of relative quantification detection mouse liver tissue PPAR γ, Fas, ACO, CPT-1.As a result such as Fig. 4 institute
Show that (- 1- low fat control group, 0- control group high in fat, 3 test group of 1- embodiment, 4 test group of 2- embodiment, 3- embodiment 5 are tried in figure
Test group, 6 test group of 4- embodiment, 7 test group of 5- embodiment, 1 control group of 6- comparative example, 2 control group of 7- comparative example, 8- comparative example
3 control groups), figure 4, it is seen that moutan root bark extract made from embodiment 3-7 can significantly lower PPAR γ, Fas base
The expression of cause inhibits fatty acid synthesis；The expression of significant up-regulation ACO, CPT-1 gene, accelerates mitochondria to free fatty acid
Intake and oxidation.And moutan root bark extract made from comparative example 1-3 to the expression of PPAR γ, Fas, ACO, CPT-1 without
It influences.This illustrates that the present invention is able to suppress fatty acid synthesis, acceleration line with the paeonol derivative that moutan root bark extract contains
Intake and oxidation of the plastochondria to free fatty acid.
1 RT-PCR primer sequence of table
Test example 3:
Functions of lowering blood-fat and reducing weight of the Weight reducing compound to the mouse of diet inducing obesity
Experimental animal is randomly divided into Normal group, fat control group, embodiment 3-7 test group and comparative example by weight
1-3 control group, every group 10.The mouse of Normal group is fed daily with normal diet, fat control group, embodiment 3-7 examination
The mouse for testing group and comparative example 1-4 control group is fed daily with high lipid food.4 every cages of mouse, 22 ± 2 DEG C of environment, humidity 30-
70%, mouse ad lib and drinking-water；Experiment lasts 8 weeks, and record weight is primary within every 7 days, and record mouse ingests and take the photograph water within every 3 days
Amount.Normal group and fat control group mice are daily with distilled water stomach-filling, remaining group mouse is then daily respectively with embodiment 3-7
With Weight reducing compound solution (5g/kg) stomach-filling of comparative example 1-3, one time a day, 1 2mL.Mouse weight is weighed weekly, and uses skin
Ruler measurement body is long, calculates Lee ' s index, as a result such as table 2, from Table 2, it can be seen that fat control group, comparative example 1-3 control group
Weight gain situation and Lee ' s index variation be apparently higher than Normal group and embodiment 3-7 test group, this illustrates the present invention
Embodiment 3-7 Weight reducing compound can significantly inhibit the body weight increase due to caused by high fat diet, but not have to the body of mouse length
Inhibiting effect；And comparative example 1-3 control group is able to suppress the body weight increase due to caused by high fat diet, but it is long to the body of mouse
There is no inhibiting effect.And 3-7 of embodiment of the present invention Weight reducing compound compares the inhibiting effect of body weight increase better than comparative example 1-3
Group.In addition, 4 control group of comparative example is on the growth of weight and body length almost without influence.
Body length, the measurement result of weight and Lee ' s index of 2 mouse of table
The prior art of routine techniques dawn known to those skilled in the art in above-described embodiment, therefore herein no longer in detail
It repeats.
The above embodiments are only used to illustrate the present invention, and not limitation of the present invention, the ordinary skill people of this field
Member can also make a variety of changes and modification without departing from the spirit and scope of the present invention.Therefore, all equivalent
Technical solution also belong to scope of the invention, scope of patent protection of the invention should be defined by the claims.
Claims (10)
1. Weight reducing compound, it is characterised in that: including moutan root bark extract；
Contain paeonol derivative shown in formula (i) in the moutan root bark extract；
In formula, R is that methyl or R are selected from carbon atom number as 1 and the group containing halogen.
2. Weight reducing compound according to claim 1, it is characterised in that: also contain the root bark of tree peony in the moutan root bark extract
Phenol.
3. according to right want 1 or 2 described in Weight reducing compound, it is characterised in that: the Weight reducing compound further include tealeaves extract
Object.
4. Weight reducing compound according to claim 3, it is characterised in that: the tea extract includes below aqueous mentions
Take object: green tea, black tea, dark green tea, Pu'er tea or oolong tea, or combinations thereof.
5. Weight reducing compound according to claim 3, it is characterised in that: the composition contain following parts by weight at
Point: 5-50 parts of moutan root bark extract, 0-20 parts of tea extract.
6. the preparation method of Weight reducing compound described in claim 1-5, it is characterised in that: include:
S1: will be added in cortex moutan powder comprising acid anhydrides, pyridine, ethyl alcohol, water extracting solution in, microwave treatment after mixing, so
It extracts afterwards and obtains extracting solution, be concentrated into medicinal extract, it is dry to get moutan root bark extract；
S2: will be added hot water in tea leaf powder, Microwave Extraction obtains extracting solution after mixing, be concentrated into medicinal extract, dry to get mentioning
Take object；
S3: the moutan root bark extract and tea extract are uniformly mixed to get Weight reducing compound.
7. the preparation method of Weight reducing compound according to claim 6, it is characterised in that: the S1 extracting solution be containing
The ethanol solution of the 80-90% of 0.1-0.4mM acid anhydrides and 7.0-30.0mM pyridine.
8. the preparation method of Weight reducing compound according to claim 6 or 7, it is characterised in that: the acid anhydrides, which is selected from, to be had
At least one of the compound of chemical structural formula shown in formula ii:
In formula, R is that methyl or R are selected from carbon atom number as 1 and the group containing halogen.
9. the preparation method of Weight reducing compound according to claim 6, it is characterised in that: microwave treatment power in the S1
For 200-800w, time 3-5min.
10. Weight reducing compound, as prepared by the described in any item preparation methods of claim 6-9.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201910444697.4A CN110279757A (en) | 2019-05-27 | 2019-05-27 | Weight reducing compound and preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201910444697.4A CN110279757A (en) | 2019-05-27 | 2019-05-27 | Weight reducing compound and preparation method thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN110279757A true CN110279757A (en) | 2019-09-27 |
Family
ID=68002774
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201910444697.4A Withdrawn CN110279757A (en) | 2019-05-27 | 2019-05-27 | Weight reducing compound and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN110279757A (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN114699356A (en) * | 2021-12-10 | 2022-07-05 | 现代百朗德生物科技(江苏)有限公司 | Cosmetic composition with fat-reducing effect and preparation method thereof |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102357128A (en) * | 2007-08-07 | 2012-02-22 | 北京北大维信生物科技有限公司 | Application of extractive of Chinese herbal medicine cortex moutan to prepare weight-losing lipid-lowering medicines or medicines with effects of inhibiting lipase activity |
| CN109248232A (en) * | 2018-11-15 | 2019-01-22 | 武汉轻工大学 | A kind of hydrogel fat-reducing plaster and preparation method thereof |
-
2019
- 2019-05-27 CN CN201910444697.4A patent/CN110279757A/en not_active Withdrawn
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102357128A (en) * | 2007-08-07 | 2012-02-22 | 北京北大维信生物科技有限公司 | Application of extractive of Chinese herbal medicine cortex moutan to prepare weight-losing lipid-lowering medicines or medicines with effects of inhibiting lipase activity |
| CN109248232A (en) * | 2018-11-15 | 2019-01-22 | 武汉轻工大学 | A kind of hydrogel fat-reducing plaster and preparation method thereof |
Non-Patent Citations (4)
| Title |
|---|
| 张巧玲，栗秀萍主编: "《化工工艺学》", 31 July 2015, 国防工业出版社 * |
| 徐艳霞主编: "《药学专业知识 1》", 31 May 2016, 中国医药科技出版社 * |
| 汪波等: "新型丹皮酚肟酯的高效合成", 《合成化学》 * |
| 谢培山，颜玉贞编著: "《中药色谱指纹图谱精细分析图集》", 30 November 2015, 福建科学技术出版社 * |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN114699356A (en) * | 2021-12-10 | 2022-07-05 | 现代百朗德生物科技(江苏)有限公司 | Cosmetic composition with fat-reducing effect and preparation method thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Kwon et al. | The lignan-rich fractions of Fructus Schisandrae improve insulin sensitivity via the PPAR-γ pathways in in vitro and in vivo studies | |
| Zheng et al. | Antihyperglycemic activity of Selaginella tamariscina (Beauv.) spring | |
| Adeneye et al. | Hypoglycemic and hypolipidemic effects of fresh leaf aqueous extract of Cymbopogon citratus Stapf. in rats | |
| Zhang et al. | Anthocyanins from Chinese bayberry extract protect β cells from oxidative stress-mediated injury via HO-1 upregulation | |
| Wang et al. | Steaming changes the composition of saponins of Panax notoginseng (Burk.) FH Chen that function in treatment of hyperlipidemia and obesity | |
| Yamaguchi et al. | β-Caryophyllene promotes osteoblastic mineralization, and suppresses osteoclastogenesis and adipogenesis in mouse bone marrow cultures in vitro | |
| Maghrani et al. | Effects of an aqueous extract of Triticum repens on lipid metabolism in normal and recent-onset diabetic rats | |
| CN105662905B (en) | Purposes of the dihydromyricetin in preparing prevention dermal photodamage skin care item or drug | |
| Kobayashi et al. | Effects of ethyl acetate extract of Kaempferia parviflora on brown adipose tissue | |
| Chehri et al. | Anti-diabetic potential of Urtica Dioica: current knowledge and future direction | |
| CN102430078A (en) | Medicine for treating acute gouty arthritis and preparation method thereof | |
| CN110279757A (en) | Weight reducing compound and preparation method thereof | |
| Yazihan et al. | Increased glucose uptake and insulin binding activity of Nerium oleander in hepatocytes and adipocytes | |
| CN109568420A (en) | The purposes of Chinese wampee seed and its extract in the food, health care product or drug of preparation treatment diabetes, obesity and hyperlipidemia | |
| Samaddar et al. | Optimization of pancreatic islet isolation from rat and evaluation of islet protective potential of a saponin isolated from fruits of Momordica dioica | |
| Tan et al. | Phytochemicals derived from soya bean husk exert hypoglycemic and anti-adipogenic properties in cell culture models | |
| US9328330B2 (en) | Anti-obesity potential of Calebin A | |
| CN113940909A (en) | Composition for regulating circadian rhythm and application thereof | |
| WO2009035253A2 (en) | Novel use of scoparone | |
| CN105363031B (en) | The purposes of α-(8- quinoline oxy) mono-substituted zinc phthalocyanine treatment psoriasis | |
| Azahari et al. | Dose water extract of cinnamon (Cinnamomum Zeylanicum) exhibits anti-diabetic properties in cultured 3T3-L1 adipocytes: A concurrent assessment of adipogenesis, lipolysis and glucose uptakes | |
| US9737502B2 (en) | Calebin A for hepatic steatosis | |
| Yokozawa et al. | Effects of Wen‐Pi‐Tang and its crude drug extracts on proliferation of cultured mouse mesangial cells | |
| Sharma et al. | Evaluation of toxicity studies of Sesbania grandiflora leaves extracts in Wistar albino rats | |
| KR101602884B1 (en) | Cosmetic compositions for slimming comprising vitamin U |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| WW01 | Invention patent application withdrawn after publication | ||
| WW01 | Invention patent application withdrawn after publication |
Application publication date: 20190927 |